Search 33,000+ CME courses
Back

Answers in CME Inc. (AiCME)

Where Do ADCs Fit in R/R DLBCL? Addressing Community Questions and Real-World Approaches to Selecting and Sequencing Novel Therapies

This enduring activity aims to improve community hematologist-oncologists , oncologists , hematologists , and APPs knowledge and competence in identifying appropriate candidates for ADCs, interpreting supporting evidence, and implementing effective, coordinated care strategies across treatment settings. As a result of this educational activity, learners should be better able to: 1. Identify patients with R/R DLBCL who may benefit from ADC therapy in the third-line or later setting; 2. Interpret current evidence to inform selection of ADC therapies for patients with R/R DLBCL in the third-line or later setting; and, 3. Discuss strategies to optimize the use of ADC therapies for patients with R/R DLBCL, particularly in the community setting. Learners have access to downloadable materials and resources for use in practice.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • Microlearning
  • Credit · Up to 0.5 credits
  • Commercial Support
  • Released
    Nov 10, 2025
  • Last day to claim credit
    Nov 10, 2026 4 weeks left

Related courses

See all

Other providers’ courses on the same topic

More from Answers in CME Inc. (AiCME)

See all

This provider’s courses closest to this one